(2022). Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK. Bmj Open, 12, e055015. http://doi.org/10.1136/bmjopen-2021-055015
. G. Villa
First name
G.
Last name
Villa
(2017). Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ. http://doi.org/10.1080/13696998.2017.1284078
. (2020). Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom. Eur J Prev Cardiol. http://doi.org/10.1177/2047487319899212
. (2021). Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom. Eur J Prev Cardiol. http://doi.org/10.1177/2047487319899212
.